There is no shortage of interest in healthcare. What has changed in 2026 is what investors expect to see before they are willing to put capital behind it.

For several years, a compelling growth story could carry considerable weight. A rapidly expanding market, an innovative technology or the possibility of scaling into new areas could be enough to attract serious attention. Those things still matter, but across healthcare investing this year, the conversation has become more demanding. Investors increasingly want to know what the growth is underneath.

How does the business operate? Where does its value actually come from? Is the leadership experienced? Are compliance and quality built into the operation? Can the company perform in a difficult reimbursement environment? And perhaps most importantly, can management demonstrate how growth will translate into sustainable results?

Those are harder questions, however they may also be healthier ones for the industry.

Plenty of Capital, but Greater Expectations

The interesting thing about the current healthcare investment environment is that capital itself is not necessarily the problem.

J.P. Morgan recently reported that healthcare private equity reached record global deal value in 2025 and that approximately 350 investors are now active in healthcare deals—nearly twice the number before the pandemic.

At the same time, an estimated $1.3 trillion in private-equity capital remains available across the broader market. There is money looking for opportunity.

What investors appear less willing to do is assume that opportunity alone will create the outcome. One of the more interesting observations coming out of J.P. Morgan’s Healthcare Growth Forum this summer was the increasing importance of what it called “operational lift.”

In simple terms, investors want businesses to show that they can actually become better businesses. That means improving operations, executing commercially, managing costs, maintaining pricing discipline and building systems that can continue performing as an organization grows.

The story matters, but execution matters more.

The Math Has Changed

Part of this shift is financial. For many years, healthcare investors benefited not only when the companies they owned grew, but also when the market was willing to pay increasingly higher valuations for those businesses. That provided another source of investment returns. Today’s environment is different.

According to analysis presented by Bain at the J.P. Morgan Healthcare Growth Forum, roughly 43% of healthcare private-equity value creation during the previous 15 years came from multiple expansion. That tailwind has weakened.

As a result, investors increasingly have to create value through the actual performance of the underlying business rather than relying on the possibility that someone will simply pay a higher multiple for it later.

That changes the questions being asked at the beginning. Instead of only asking, “How large could this become?” Investors are also asking: “How does this become better?”

Healthcare Makes That Question Particularly Important

Running a healthcare business is difficult. There are reimbursement pressures, workforce shortages, regulatory requirements, patient expectations, technology changes and rising operating costs.

Unlike many other industries, healthcare organizations have to manage those pressures while operating in an environment where quality and compliance can never become secondary considerations.

That complexity is one reason specialized knowledge is becoming increasingly valuable. Healthcare isn’t one business model.

A medical practice operates differently from a biotechnology company. A medical technology developer faces different challenges from a revenue-cycle company. A specialty finance platform requires another set of capabilities entirely. Understanding those differences matters.

McKinsey reported earlier this year that healthcare investment professionals increasingly view operational execution as a greater driver of near-term performance than financial engineering. Compliance, quality management and specialized operating expertise were also identified as important components of value creation.

That tells us something about where healthcare investing may be heading. The market isn’t abandoning growth. It is asking growth to prove itself.

Innovation Still Matters, But So Does What Surrounds It

This is particularly relevant in healthcare because innovation remains one of the industry’s greatest attractions. New medical devices, biotechnology, regenerative medicine, artificial intelligence and healthcare technology continue creating possibilities that would have been difficult to imagine not long ago.

Capital is still following many of those developments, but investors are becoming more selective about what qualifies as meaningful innovation.

A technology can be impressive and still face questions about implementation. A clinical concept can be promising and still require years of validation. An AI product can perform well in a demonstration and still struggle when introduced into an actual healthcare workflow.

The distinction between something that can work and something that can work consistently within a real healthcare environment is becoming increasingly important. That is a useful distinction well beyond investing.

What This Means From PFD’s Perspective

This shift is interesting to us because many of the qualities receiving greater attention across healthcare investing are familiar ones at PFD. Our approach has long emphasized structure, compliance, operational discipline, communication and risk awareness alongside opportunity.

Those principles apply differently across the PFD Family of Companies. Within healthcare-linked specialty finance, the work involves medical receivables, providers, servicing, documentation, compliance and the systems required to manage those assets.

Within medical innovation, the questions are different. Scientific validity, intellectual property, clinical development, regulatory progress, leadership and ultimately patient outcomes become increasingly important. Different opportunities require different forms of evaluation, but the underlying philosophy is similar.

An interesting idea is not enough by itself. There has to be substance behind it.

A More Mature Healthcare Investment Market

None of this means healthcare investors have suddenly become pessimistic. It is quite the opposite. Healthcare continues to attract significant capital, and current deal activity suggests investors still see substantial long-term opportunity across the industry.

What appears to be changing is the definition of a good opportunity. Growth, innovation, and market size still matters.

Also increasingly, so do the less exciting questions: Can the organization execute? Can it manage complexity? Can it demonstrate measurable improvement? Can it operate responsibly? Can it withstand difficult periods? And does the opportunity make sense without depending on everything going perfectly?

Those questions don’t make healthcare investing less ambitious; they make it more disciplined.

Raising the Bar Can Be a Good Thing

Markets have a way of changing what they reward. There are periods when speed receives the most attention. Other periods reward scale, novelty or aggressive expansion. 2026 appears to be reminding healthcare investors of something more fundamental.

A compelling opportunity still has to become a good business, and a good business still has to perform. For investors, that higher standard may mean passing on opportunities that look exciting but lack the infrastructure to support their promise.

For healthcare companies, it means demonstrating more than potential. For those of us working inside the healthcare and finance ecosystem, it is an encouraging development to watch. When capital becomes more thoughtful about where it goes, the strongest ideas are not necessarily the ones that make the most noise.

They are the ones capable of standing up to the harder questions.